Systemic treatment of HER2-positive metastatic breast cancer: A systematic review

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue S4, 2014, Pages 1-14

  Wilcken, Nicholas ^a   Zdenkowski, Nicholas ^b   White, Michelle ^c   Snyder, Ray ^d   Pittman, Ken ^e   Mainwaring, Paul ^f   Green, Michael ^g   Francis, Prudence ^h   De Boer, Richard ⁱ   Colosimo, Maree ^f   Chua, Sue ^j   Chirgwin, Jacquie ^k   Beith, Jane ^l   Bell, Richard ^m  

^a WESTMEAD HOSPITAL   (Australia)

^b Australia and New Zealand Breast Cancer Trials Group   (Australia)

^c CABRINI HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f Mater Private Breast Cancer Centre   (Australia)

^g Western Health ^*  (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j Epworth Eastern   (Australia)

^k BOX HILL HOSPITAL   (Australia)

^l Chris O'Brien Lifehouse   (Australia)

^m DEAKIN UNIVERSITY   (Australia)

more..

Author keywords

Anti HER2 agent; Breast cancer; Metastatic; Review; Systematic

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; DRUG SAFETY; HEART DISEASE; HER2 POSITIVE METASTATIC BREAST CANCER; HORMONAL THERAPY; HUMAN; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCT SAFETY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84899867831     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12206     Document Type: Article

References (85)

1. Cancer Australia. Breast cancer in Australia: an overview. 2012.
2. Cancer Australia. Recommendations for Use of Trastuzumab (Herceptin) for the Treatment of HER2-Positive Breast Cancer). Canberra, Cancer Australia March 2007.
3. Roche Products Pty Ltd. Pertuzumab Product Information. 2013.
4. Roche Products Pty Ltd. Trastuzumab Product Information. 2013.
5. Roche Products Pty Ltd. Trastuzumab emtansine Product Information. 2013.
6. GlaxoSmithKline Australia Pty Ltd. Lapatinib Product Information. 2013.
7. Medicare. Late Stage Metastatic Breast Cancer. 2014.
8. Wilcken N. Systematic Review Protocol: systemic treatment of HER2+ metastatic breast cancer. 2013.
9. Saad ED, Katz A, Hoff PM etal. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010; 21: 7-12.
10. Andersson M, Lidbrink E, Bjerre K etal. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264-271.
11. Huober J, Fasching PA, Barsoum M etal. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012; 21: 27-33.
12. Slamon DJ, Leyland-Jones B, Shak S etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
13. von Minckwitz G, du Bois A, Schmidt M etal. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
14. Marty M, Cognetti F, Maraninchi D etal. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
15. Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 2001; 12 (Suppl 1): S57-62.
16. Osoba D, Slamon DJ, Burchmore M etal. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-3113.
17. Slamon D, Leyland Jones B, Shak S etal. Addition of Herceptin(tm) (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol 1998; 98a: Abstract 377.
18. Tripathy D, Seidman A, Keefe D etal. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004; 5: 293-298.
19. Extra JM, Cognetti F, Chan S etal. Randomised phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer [abstract].). Eur J Cancer 2003; S202: abstract 672.
20. Extra JM, Cognetti F, Maraninchi D etal. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer [abstract]). Clin Oncol 2005; 23: 17, abstract 555.
21. Geyer CE, Forster J, Lindquist D etal. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.[Erratum appears in N Engl J Med. 2007 Apr 5;356(14):1487]. NEJM 2006; 355: 2733-2743.
22. Cameron D, Casey M, Oliva C etal. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924-934.
23. Cameron D, Casey M, Press M etal. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
24. Crown J. Lapatinib (L) plus capecitabine in HER2-positive metastatic breast cancer (MBC): an exploratory analysis of overall survival (OS) based on poststudy therapy. Ann Oncol 2010; 21: viii101: abstract 291P.
25. Sherrill B, Amonkar MM, Stein S etal. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.). Br J Cancer 2008; 711-715.
26. Zhou X, Cella D, Cameron D etal. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117: 577-589.
27. Gasparini G, Gion M, Mariani L etal. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007; 101: 355-365.
28. Gasparini G. Interim analysis of a randomised phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC): clinical and biological results. ASCO 2003; Abstract 138.
29. Schwartzberg LS, Franco SX, Florance A etal. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.[Erratum appears in Oncologist. 2010;15(3):327 Note: Schwarzberg, Lee S [corrected to Schwartzberg, Lee S]]. Oncologist 2010; 15: 122-129.
30. Johnston S, Pippen J Jr, Pivot X etal. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
31. Ro J. Safety of first-line letrozole compared with lapatinib plus letrozole in patients with potmenopausal hormone receptor positive metastatic breast cancer: EGF30008 study. Cancer Res 2009; 69: 796s, abstract 5094.
32. Sherrill B. An exploration of the association of quality of life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ metastatic breast cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Cancer Res 2009; 69: 801s, abstract 5106.
33. Sherrill B, Amonkar MM, Stein S etal. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008; 99: 711-715.
34. von Minckwitz G, Zielinski C, Maarteense E etal. Capecitabine vs. capecitabine+ trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3 05) [abstract no. 1025]). J Clin Oncol 2008; 26: 1025.
35. von Minckwitz G, Schwedler K, Schmidt M etal. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47: 2273-2281.
36. Kaufman B, Mackey JR, Clemens MR etal. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
37. Guan Z, Xu B, DeSilvio ML etal. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 2013; 31: 1947-1953.
38. Guan Z, Xu B, DeSilvio M etal. Lapatinib (L) in combination with Paclitaxel (P) is an effective and tolerable treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) patients. Eur J Cancer 2011; 47: S345.
39. Blackwell KL, Burstein HJ, Storniolo AM etal. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
40. Blackwell K. Updated survival analysis of a randomised study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2009; 69: Abstract 61.
41. Blackwell KL, Burstein HJ, Storniolo AM etal. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012; 30: 2585-2592.
42. O'Shaughnessy J, Blackwell KL, Burstein H etal. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract no. 1015].). J Clin Oncol 2008; 26: 1015.
43. Wu Y, Amonkar MM, Sherrill BH etal. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.). Ann Oncol 2011; 2582-2590.
44. Baselga J, Cortes J, Kim S-B etal. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEJM 2012; 366: 109-119.
45. Abraham J. Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Community Oncol 2012; 9: 42-44.
46. Baselga J, Cortes J, Im SA etal. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012; 72: abstract nr S5-1.
47. Swain SM, Ewer MS, Cortes J etal. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013; 18: 257-264.
48. Gelmon KA, Boyle F, Kaufman B etal. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012; 30: LBA671.
49. Parulekar W, Chapman JW, Aparicio S etal. Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). J Clin Oncol 2011; 29: TPS108.
50. Verma S, Miles D, Gianni L etal. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEJM 2012; 367: 1783-1791.
51. Krop ILN, Blackwell K, Guardino E etal. Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: results from a retrospective exploratory analysis of EMILIA. SABCS 2013; 1190.
52. Wang B, Jin J, Wada R etal. Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2013; 644.
53. Elias AMS, Krop IE, Pegram M etal. Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer. SABCS 2013; 1520.
54. Martin MA. A phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer. Clin Adv Hematol Oncol 2012; 10: 12-13.
55. Martin MA. Phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer. Clin Adv Hem On 2011; 10(Suppl 2): 12-13.
56. Hurvitz SA, Dirix L, Kocsis J etal. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31: 1157-1163.
57. Hurvitz S, Dirix L, Kocsis J etal. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450 g/BO21976). Eur J Cancer 2011; 47: S330.
58. Perez EA. Efficacy and Safety of Trastuzumab-DM1 versus trastuzumab plus docetaxel in HER-2 positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomised, multicenter, open-label phase 2 study (TDM4450G). Ann Oncol 2010; 21(Suppl 8): LBA3.
59. Martin M, Bonneterre J, Geyer CE Jr etal. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013; 49: 3763-3772.
60. Wildiers H. T-DM1 for HER2-positive metastatic breast cancer (MBC): primary result from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. ESMO 2013; abstract 15.
61. Robert N, Leyland-Jones B, Asmar L etal. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 - Overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-2792.
62. Robert NJ, Leyland JB, Asmar L etal. Randomized phase III trial study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival [abstract]. J Clin Oncol 2004; 22, 14S, 573.
63. Burstein HJ, Keshaviah A, Baron AD etal. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110: 965-972.
64. Wardley AM, Pivot X, Morales-Vasquez F etal. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 976-983.
65. Bell R. Beyond CHAT: overall survival (OS) update from the Chat study of first line trastuzumab plus docetaxel with or without capecitabine in HER2-positive metastatic breast cancer (MBC). Ann Oncol 2010; 21: viii99, 283PD.
66. Untch M, Muscholl M, Tjulandin S etal. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-1480.
67. Inoue K, Nakagami K, Mizutani M etal. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010; 119: 127-136.
68. Valero V, Forbes J, Pegram MD etal. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011; 29: 149-156.
69. Forbes JF, Kennedy J, Pienkowski T etal. BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC): main time to progression (TTP) analysis. J Clin Oncol 2006; 24: 18S, LBA516.
70. Lankjer ST. First line therapy of metastatic or locally advanced HER2-positive breast cancer: update of the HERNATA study. ESMO 2013; abstract 1913.
71. Hamberg P, Bos MMEM, Braun HJJ etal. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011; 11: 103-113.
72. Bontenbal M, Seynaeve C, Stouthard J etal. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) [abstract no. 1014]). J Clinl Oncol 2008, 26: 15S, 1014.
73. De La Pena L, Cortes J, Manikhas A etal. Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC). J Clin Oncol 2013; 31: 517.
74. Gomez HNS, Tosello C, Mano M etal. A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801). SABCS 2013; 1030.
75. Papadimitriou CA, Sarosiek T, Pikiel J etal. A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC). J Clin Oncol 2013; 31: 516.
76. Vogel CL, Cobleigh MA, Tripathy D etal. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
77. Vogel CL, Cobleigh MA, Tripathy D etal. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61: 37-42.
78. Cortes J, Baselga J, Kellokumpu LP etal. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 [abstract]. J Clin Oncol 2005; 3068.
79. Gomez HL, Doval DC, Chavez MA etal. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26: 2999-3005.
80. Arteaga CL, Mayer IA, O'Neill AM etal. A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): a trial of the Eastern Cooperative Oncology Group (E1105). J Clin Oncol 2012; 30: 605.
81. Gianni L, Romieu GH, Lichinitser M etal. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719-1725.
82. Gianni L, Romieu G, Lichinitser M etal. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2011; 71: S4-8.
83. Johnston SRD, Gomez H, Stemmer SM etal. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013; 137: 755-766.
84. Slamon D, Gomez HL, Kabbinavar FF etal. Randomized study of pazopanib+lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract no. 1016]). J Clin Oncol 2008; 45: 1016.
85. Cardoso F, Costa A, Norton L etal. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21: 242-252.